KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Novavax (NVAX) EPS (Basic) (2016 - 2025)

Novavax has reported EPS (Basic) over the past 16 years, most recently at $0.11 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.11 for Q4 2025, up 121.15% from a year ago — trailing twelve months through Dec 2025 was $2.74 (up 320.97% YoY), and the annual figure for FY2025 was $2.72, up 321.14%.
  • EPS (Basic) for Q4 2025 was $0.11 at Novavax, up from -$1.25 in the prior quarter.
  • Over the last five years, EPS (Basic) for NVAX hit a ceiling of $3.22 in Q1 2025 and a floor of -$11.31 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$1.25 (2025), compared with a mean of -$1.79.
  • Biggest five-year swings in EPS (Basic): plummeted 1483.33% in 2021 and later soared 406.67% in 2025.
  • Novavax's EPS (Basic) stood at -$11.31 in 2021, then soared by 79.75% to -$2.29 in 2022, then skyrocketed by 35.81% to -$1.47 in 2023, then surged by 64.63% to -$0.52 in 2024, then surged by 121.15% to $0.11 in 2025.
  • The last three reported values for EPS (Basic) were $0.11 (Q4 2025), -$1.25 (Q3 2025), and $0.66 (Q2 2025) per Business Quant data.